Navigation Links
Viral recombination another way HIV fools the immune system
Date:7/21/2008

of the Gag protein typically targeted in HLA-B27 patients.

Analysis after the abrupt increase in viral levels showed that the patient had become infected with a second strain of HIV, and two months later it was found that the two strains had exchanged portions of their Gag sequences initially targeted by his CTLs, allowing the virus to escape from that immune response. The patient's viral loads stabilized for a while but rose again several months later, when it was found that a second HIV mutation that more effectively evades control by HLA-B27 had developed, possibly in response to a second recombination of viral sequences.

"The first Gag recombination event facilitated escape from the primary immune response, shortly after which the immune response recovered to recognize this mutant strain," Streeck explains. "After the second recombination event and emergence of a more potent mutation, there was a dramatic reduction in the CTL response against both versions, leading to a significant increase in viral loads."

Todd Allen, PhD, of PARC-MGH, the study's senior author adds that, while recombination itself appears to be a random event, recombinant strains that are better able to evade the immune system are likely to become dominant through natural selection. He also stresses that even patients whose immune systems can partially control HIV should avoid a secondary infection that could lead to the development of an uncontrollable, recombinant viral strain.

Streeck notes, "Given the growing frequency of recombinant HIV strains worldwide, we need to better understand how immune system pressures may be driving their development and also determine how frequently patients exposed to a second strain of HIV become superinfected." He is a research fellow in Medicine at Harvard Medical School, where Allen is an associate professor of Medicine.


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. Clearance of hepatitis C viral infection after liver transplantation
2. Feline virus, antiviral drug studied to understand drug resistance
3. Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports
4. Tumor-targeting viral therapy slows neuroblastoma, malignant peripheral nerve sheath tumors
5. Scientists discover DNA knot keeps viral genes tightly corked inside shell
6. Control switches found for immune cells that fight cancer, viral infection
7. A viral cloaking device
8. Human RecQ helicases, homologous recombination and genomic instability
9. One species entire genome discovered inside anothers
10. Same gene protects from 1 disease, opens door to another
11. Another type of nanotube, a how-to guide to making bamboo-structured carbon nanotubes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...E, Ind. - Researchers at Purdue University have di...e fibers in spinal cord injuries using nano-sphere...ter an accident. , The synthetic "copolymer mice...s in diameter, or roughly 100 times smaller than t...ave been studying how to deliver drugs for cancer ...
(Date:11/6/2009)...stration is now open for the Society of Interventi...logy (IO) Therapies" Webinar, which will provide t...r treatment of liver tumors, kidney tumor ablation...zation of physicians, scientists and allied health...h through pioneering advances in image-guided ther...
(Date:11/6/2009).... 6 Auburn Hills, MI-based Law Enf...nstalling its locker system and patent-pending Bio.... Department of Health and Human Services, Nationa.... The locker system will support the NIH,s entire...ur nation,s medical research agency. The project ...
Breaking Biology News(10 mins):Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 1Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 2Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 3New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 1New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 2New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 3New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 4New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 5New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 6New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 7New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 8New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 9New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 10New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 11New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 12New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 13New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 14New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 15New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 16New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 17New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 18New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 19New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 20New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 21New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 22Hologic Expands Healthcare Investment in Asia 5563 1Hologic Expands Healthcare Investment in Asia 5563 2Hologic Expands Healthcare Investment in Asia 5563 3
...which trauma and burn patients are most likely to ...wide range of experimental clinical settings ?an i...outinely used in emergency rooms and intensive car...in the Proceedings of the National Academy of Scie...ng the University of Florida, describe how they we...
...iego (UCSD) have found that Lafora disease, an inh...he age of 30, can be caused by mutations in a gene...aforin. These findings are reported in the current...ciences (PNAS). , Lafora disease is characterized ..., followed by an initial seizure in the second dec...
...cancers from Nigeria, Senegal and North America ha...kely to be diagnosed with a more virulent form of ...searchers from the University of Chicago, working ...geria and the University of North Carolina, found ...ferent pattern of gene expression. Tumors from Afr...
Other Biology News:Doctors closer to using gene analysis to help trauma patients 2Doctors closer to using gene analysis to help trauma patients 3UCSD research reveals mechanism involved with type of fatal epilepsy 2Study reveals dramatic difference between breast cancers in US and Africa 2Study reveals dramatic difference between breast cancers in US and Africa 3Study reveals dramatic difference between breast cancers in US and Africa 4
(Date:11/9/2009)...ewswire/ -- For more than 20 years,researchers all...nt of a,Brain-Computer Interface (BCI). This is a ... a computer. Such a system enables completely para...s in their environment just by,mental activity. Du...ised by,the researchers themselves to use such BCI...
(Date:11/9/2009)...research industry first, allowing veterinary resea...ety study data to be managed in one software appli...J (PRWEB) November 9, 2009 -- Xybion Medical Syste...rade; VM, an integrated enterprise software soluti...care of veterinary research subjects. Pristima&tra...
(Date:11/6/2009)...Microbix Biosystems Inc. (the "Company") announces...ification of Annual Filings of William Gastle, the... Financial Officer (the "Officer,s Certificates") ...al audited financial statements for the year ended...iled the annual financial statements for the year ...
(Date:11/6/2009)...stCall/ -- ,, 3Q09 Corporate Highlights: ,...ting Authorization to Astellas Pharma Europe Ltd. ...s activities Expanded management team to include ..., Commercial Operations Appointed Bradford S. Goo...rman , Upcoming 2009 Milestones: ,, F...
Breaking Biology Technology:intendiX - Communication by Thoughts: First Patient-Ready System on the Market 2Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management 2NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10
...he Maryland Stem Cell Research,Commission (Commiss... for,new post-doctoral fellowship grants under RFA...applications from pre-doctoral students and post-,...translational research on,all types of human stem ... fellowships will be funded with each,fellowship b...
...Raptor,Pharmaceuticals Corp. ("Raptor" or the "Com... that its clinical development division, Bennu,Pha...al product candidate,EC Cysteamine. Bennu received... developed by clinical scientists at the Universit... way of its acquisition by,merger of Encode Pharma...
... 17 , - New Deal Provides a Further Opportunity f... Oxford Genome Sciences (UK) Ltd "OGeS" announces...oration with Amgen to discover, develop and,commer...ment of cancer.,This new collaboration will enable...human therapeutic antibodies (mAbs) in cancer base...
Other Biology Technology:Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants 2Raptor Pharmaceuticals Acquires Orphan Clinical Program 2Raptor Pharmaceuticals Acquires Orphan Clinical Program 3Raptor Pharmaceuticals Acquires Orphan Clinical Program 4Raptor Pharmaceuticals Acquires Orphan Clinical Program 5Raptor Pharmaceuticals Acquires Orphan Clinical Program 6Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 2Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 3
Rabbit Anti-Chicken IgY, IgG F(ab')2 fragment Antibody, Biotin Conjugated from Biomeda Corporation
Anti-Chloride Channel, CLC-2 Polyclonal Antibody, Unconjugated from CHEMICON
... 2, Monoclonal Antibody, Unconjugated Applicati...ICC: Use at an assay dependent dilution. WB: Use a...ion is determined using a whole extract of rat bra... in other applications. Optimal dilutions/concent...
Anti-TWIK-2 (Kcnk6, TOSS) Polyclonal Antibody, Unconjugated from CHEMICON
Biology Products: